Whether it’s tablets, vaccines, or modern biotech therapies—wherever pharmaceuticals are produced, the manufacturing environment is a critical factor. Good Manufacturing Practice (GMP) requires that products not only be effective and safe but also be manufactured under strictly controlled conditions.
Cleanrooms are at the heart of pharmaceutical and biotechnology production: They create the controlled environment that minimizes cross-contamination and particle contamination—and thus lay the foundation for patient safety and regulatory compliance. In this article, we provide a step-by-step guide to the applicable requirements, how cleanroom classes (GMP A–D / ISO 14644) work, and how to plan, build, qualify, and operate GMP cleanrooms—including typical best practices.
Cleanrooms are subject to a clear, internationally harmonized set of regulations. Key requirements include:
Regulatory agencies such as the EMA, FDA, or national inspectorates pay particular attention during inspections to:
Practical Note: Many findings during GMP inspections do not relate to the technology itself, but rather to a lack of documentation or unclear interfaces between planning, operations, and quality assurance.
What is a cleanroom class?
Cleanroom classes are defined levels of cleanliness for controlled environments. They specify which particle concentrations (per m³ of air—depending on particle size) and—in the context of GMP for sterile manufacturing—which microbiological requirements are permissible in a given area. Technically, the classification is based on ISO 14644-1; for sterile pharmaceuticals, EU GMP Annex 1 describes Grades A–D. Both systems serve different purposes and are not directly interchangeable—correspondence is only possible to a limited extent.
Operating conditions according to ISO 14644:
Key point: GMP grades define the hygienic environment specifically for sterile pharmaceutical processes, while ISO 14644 classifies the particle-based cleanliness of rooms. Combining both perspectives leads to the correct selection of the cleanroom class for each process step.
| GMP Class | Typical Application | Approximately Equivalent to ISO Class | Airflow |
|---|---|---|---|
| A | Aseptic operations, filling, open sterile products | ISO ~4.8 | unidirectional (laminar) |
| B | Background for Class A (e.g., aseptic manufacturing) | ISO ~5 | turbulent / partially unidirectional |
| C | Less critical sterile steps (e.g., formulation prior to sterile filtration) | ISO ~7 | turbulent |
| D | Preparatory/non-critical production steps | ISO ~8 | turbulent |
Planning is the most critical step—errors in planning can only be corrected later with immense effort and at great cost.
Key planning principles:
Key point: A cleanroom is only as good as its weakest link—a poorly planned airlock and material flow concept can negate even the best filtration technology.
When it comes to construction, the details matter—and these are often scrutinized during audits:
Cleanrooms must be qualified before commissioning and on a regular basis during operation. This is done in four steps:
Typical tests:
Important: Any change (modification, new equipment, new airlock) is subject to change control and must be documented and evaluated.
A cleanroom is not a static project—it thrives on consistent operation.
Key elements:
Best Practice: Early, interdisciplinary planning (architects, process engineers, GMP experts, operators) saves costs in the long term and prevents retrofits.
Cleanrooms are more than just sterile rooms—they are highly complex systems that form the backbone of pharmaceutical and biotechnology production. Those who design, build, and operate GMP-compliant cleanrooms lay the foundation for safe medicines, regulatory compliance, and long-term competitiveness.
Future Trends:
The planning and implementation of GMP cleanrooms require experience at the intersection of technology, regulations, and processes.
For years, io has been supporting pharmaceutical and biotech companies in:
This results in customized solutions that are not only regulatory-compliant but also efficient and future-proof—helping companies bring their products to market faster and more safely.
Comprehensive Solutions for the Pharmaceutical, Biotech, and Life Sciences Industries
Investment in the construction of a new production building at the Bensheim site.
Successful production thrives on efficient processes. Being future-proof is the key success factor.
Comprehensive Solutions for the Pharmaceutical, Biotech, and Life Sciences Industries
Investment in the construction of a new production building at the Bensheim site.
Successful production thrives on efficient processes. Being future-proof is the key success factor.